Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05786716
Title DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Teenage/Young Adult and Paediatric Patients With Cancers With HER2 Amplification or Activating Mutations (DETERMINE)
Acronym DETERMINE
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Cancer Research UK
Indications
Therapies
Age Groups: child | adult | senior
Covered Countries GBR


No variant requirements are available.